Sinovac Life Sciences has secured around US$500 million in funding to grow, expand capability and produce its COVID-19 vaccine candidate, CoronaVac...
Sinovac Confirms $500 Million Towards COVID-19 Vaccine Research
sinovac
Sinovac Announces Positive Preliminary PI/PII Results for “CoronaVac”
Sinovac, a Beijing-based company producing a vaccine for COVID-19 today announced their "CoronaVac" vaccine concluded preliminary Phase I/II trials showing "favorable immunogenicity and safety profiles."
Sinovac to Begin Final Phase of COVID-19 Vaccine Testing in Brazil
Sinovac today announced the signing of a clinical development collaboration agreement to advance the clinical trials of CoronaVac, Sinovac’s inactivated vaccine candidate against COVID-19 to Phase III.